Berberine Inhibits Inflammatory Response and Ameliorates Insulin Resistance in Hepatocytes
Purchase on Springer.com
$39.95 / €34.95 / £29.95*
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.
Berberine, a major isoquinoline alkaloid present in Chinese herb Rhizoma coptidis, is a potent inhibitor of inflammation and has anti-diabetic activity. This study aims to investigate effects of berberine on ameliorating insulin resistance and molecular mechanisms involved in HepG2 cells. Inflammatory responses and insulin resistance were induced by palmitate (PA) stimulation for 24 h. Treatment of berberine enhanced insulin-mediated glycogen synthesis and restored insulin inhibition of triglyceride secretion. Stimulation of PA resulted in IL-6 and TNF-α production in HepG2 cells, and antibody-neutralizing assay further confirmed that IL-6 and TNF-α were involved in the development of insulin resistance. Berberine effectively inhibited IL-6 and TNF-α production in a concentration-dependent manner, demonstrating its anti-inflammatory activity in hepatocytes. Meanwhile, PA-evoked inflammation impaired insulin signaling cascade and berberine improved insulin signaling cascade by modification of Ser/Thr phosphorylation of insulin receptor substrate-1(IRS-1) and downstream Akt (T308). Above results suggest that berberine improved insulin sensitivity in PA-stimulated hepatocytes and this regulation might relative with its anti-inflammatory activity.
- Mokdad, A.H., E.S. Ford, B.A. Bowman, W.H. Dietz, F. Vinicor, V.S. Bales, and J.S. Marks. 2003. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. Journal of the American Medical Association 289: 76–79. CrossRef
- Hotamisligil, G.S., N.S. Shargill, and B.M. Spiegelman. 1993. Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance. Science 259: 87–91. CrossRef
- Feinstein, R., H. Kanety, M.Z. Papa, B. Lunenfeld, and A. Karasik. 1993. Tumor necrosis factor-α suppresses insulin-induced tyrosine phosphorylation of insulin receptor and its substrates. Journal of Biological Chemistry 268: 26055–26058.
- Hotamisligil, G.S. 2003. Inflammatory pathways and insulin action. International Journal of Obesity and related Metabolic Disorders 27(Suppl 3): S53–S55. CrossRef
- Moller, D.E. 2000. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type 2 diabetes. Trends in Endocrinology and Metabolism 11: 212–217. CrossRef
- Yuan, M., N. Konstantopoulos, J. Lee, L. Hansen, Z.W. Li, M. Karin, and S.E. Shoelson. 2001. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293: 1673–1677. CrossRef
- Hundal, R.S., K.F. Petersen, A.B. Mayerson, P.S. Randhawa, S. Inzucchi, S.E. Shoelson, and G.I. Shulman. 2002. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. Journal of Clinical Investigation 109: 1321–1326.
- Kuhlmann, J., C. Neumann-Haefelin, U. Belz, J. Kalisch, H.P. Juretschke, M. Stein, E. Kleinschmidt, W. Kramer, and A.W. Herling. 2003. Intramyocellular lipid and insulin resistance: a longitudinal in vivo 1 H-spectroscopic study in Zucker diabetic fatty rats. Diabetes 52: 138–144. CrossRef
- Dresner, A., D. Laurent, M. Marcucci, M.E. Griffin, S. Dufour, G.W. Cline, L.A. Slezak, D.K. Andersen, R.S. Hundal, D.L. Rothman, K.F. Petersen, and G.I. Shulman. 1999. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. Journal of Clinical Investigation 103: 253–259. CrossRef
- Cai, D., M. Yuan, D.F. Frantz, P.A. Melendez, L. Hansen, J. Lee, and S.E. Shoelson. 2005. Local and systemic insulin resistance resulting from hepatic activation of IKK-beta and NF-kappaB. Nature Medicine 11(2): 183–190. CrossRef
- Seppälä-Lindroos, A., S. Vehkavaara, A.M. Häkkinen, T. Goto, J. Westerbacka, A. Sovijärvi, J. Halavaara, and H. Yki-Järvinen. 2002. Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. Journal of Clinical Endocrinology and Metabolism 87: 3023–3028. CrossRef
- Ryysy, L., A.M. Häkkinen, T. Goto, S. Vehkavaara, J. Westerbacka, J. Halavaara, and H. Yki-Järvinen. 2000. Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49: 749–758. CrossRef
- Lau, C.W., X.Q. Yao, Z.Y. Chen, W.H. Ko, and Y. Huang. 2001. Cardiovascular actions of berberine. Cardiovascular Drug Reviews 19: 234–244. CrossRef
- Zhang, Y., X. Li, D. Zou, W. Liu, J. Yang, N. Zhu, L. Huo, M. Wang, J. Hong, P. Wu, G. Ren, and G. Ning. 2008. Treatment of type 2 diabetes and dyslipidemia with the natural plant alkaloid berberine. Journal of Clinical Endocrinology and Metablism 93: 2559–2565. CrossRef
- Lee, Y.S., W.S. Kim, K.H. Kim, M.J. Yoon, H.J. Cho, Y. Shen, J.M. Ye, C.H. Lee, W.K. Oh, C.T. Kim, C. Hohnen-Behrens, A. Gosby, E.W. Kraegen, D.E. James, and J.B. Kim. 2006. Berberine, a natural plant product, activates AMP-activated protein kinase with beneficial metabolic effects in diabetic and insulin-resistant states. Diabetes 55: 2256–2264. CrossRef
- Yin, J., R. Hu, M. Chen, J. Tang, F. Li, Y. Yang, and J. Chen. 2002. Effects of berberine on glucose metabolism in vitro. Metabolism 51: 1439–1443. CrossRef
- Leng, S.H., F.E. Lu, and L.J. Xu. 2004. Therapeutic effects of berberine in impaired glucose tolerance rats and its influence on insulin secretion. Acta Pharmacological Sinica 25: 496–502.
- Ko, B.S., S.B. Choi, S.K. Park, J.S. Jang, Y.E. Kim, and S. Park. 2005. Insulin sensitizing and insulinotropic action of berberine from Coptidis Rhizoma. Biological and Pharmaceutical Bulletin 28: 1431–1437. CrossRef
- Jeong, H.W., K.C. Hsu, J.W. Lee, M. Ham, J.Y. Huh, H.J. Shin, W.S. Kim, and J.B. Kim. 2009. Berberine suppresses proinflammatory responses through AMPK activation in macrophages. American Journal of Physiology-Endocrinology and Metabolism 296: 955–964. CrossRef
- Choi, B.H., I.S. Ahn, Y.H. Kim, J.W. Park, S.Y. Lee, C.K. Hyun, and M.S. Do. 2006. Berberine reduces the expression of adipogenic enzymes and inflammatory molecules of 3T3–L1 adipocyte. Experimental and Molecular Medicine 38: 599–605.
- Baldeweg, S.E., A. Golay, A. Natali, B. Balkau, S. Del Prato, and S.W. Coppack. 2000. Insulin resistance, lipid and fatty acid concentrations in 867 healthy Europeans. European Group for the Study of Insulin Resistance (EGIR). European Journal of Clinical Investigation 30: 45–52. CrossRef
- Bradford, M. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical Biochemistry 72: 248–254. CrossRef
- Bolinder, J., D.A. Kerckhoffs, E. Moberg, E. Hagstrom-Toft, and P. Arner. 2000. Rates of skeletal muscle and adipose tissue glycerol release in nonobese and obese subjects. Diabetes 49: 797–802. CrossRef
- Boden, G. 1997. Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46: 3–10. CrossRef
- Kelley, D.E., and L.J. Mandarino. 2000. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 49: 677–683. CrossRef
- Lewis, G.F., A. Carpentier, K. Adeli, and A. Giacca. 2002. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocrine Reviews 23: 201–229. CrossRef
- Kelley, D.E., T.M. McKolanis, R.A. Hegazi, L.H. Kuller, and S.C. Kalhan. 2003. Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance. American Journal of Physiology 285: 906–916.
- Shi, H., M.V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J.S. Flier. 2006. TLR4 links innate immunity and fatty acid-induced insulin resistance. Journal of Clinical Investigation 116: 3015–3025. CrossRef
- Jeong, H.W., K.C. Hsu, J.W. Lee, M. Ham, J.Y. Huh, H.J. Shin, W.S. Kim, and J.B. Kim. 2009. Berberine suppresses pro-inflammatory responses through AMPK activation in macrophages. American Journal of Physiology-Endocrinology and Metabolism 296: E955–E964. CrossRef
- Senn, J.J., P.J. Klover, I.A. Nowak, and A. Robert. 2002. Mooney Interleukin-6 Induces Cellular Insulin Resistance in Hepatocytes. Diabetes 51: 3391–3399. CrossRef
- Hotamisligil, G.S., P. Peraldi, A. Budavari, R. Ellis, M.F. White, and B.M. Spiegelman. 1996. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α and obesity-induced insulin resistance. Science 1996(271): 665–668. CrossRef
- Uysal, K.T., S.M. Wiesbrock, M.W. Marino, and G.S. Hotamisligil. 1997. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 389: 610–614. CrossRef
- Hotamisligil, G.S., A. Budavari, D. Murray, and B.M. Spiegelman. 1994. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes central role of tumor necrosis factor-α. Journal of Clinical Investigation 94: 1543–1549. CrossRef
- Cheung, A.T., D. Ree, J.K. Kolls, J. Fuselier, D.H. Coy, and M. Bryer-Ash. 1998. An in vivo model for elucidation of the mechanism of tumor necrosis factor—(TNF-α)-induced insulin resistance: evidence for differential regulation of insulin signaling by TNF-α. Endocrinology 139: 4928–4935. CrossRef
- Cheung, A.T., J. Wang, D. Ree, J.K. Kolls, and M. Bryer-Ash. 2000. Tumor necrosis factor-induces hepatic insulin resistance in obese Zucker (fa/fa) rats via interaction of leukocyte antigen-related tyrosine phosphatase with focal adhesion kinase. Diabetes 49: 810–819. CrossRef
- Yamada, Y., E.M. Webber, I. Kirillova, J.J. Peschon, and N. Fausto. 1998. Analysis of liver regeneration in mice lacking type 1 or type 2 tumor necrosis factor receptor: requirement for type 1 but not type 2 receptor. Hepatology 28: 959–970. CrossRef
- Campbell, J.S., L. Prichard, F. Schaper, J. Schmitz, A. Stephenson-Famy, M.E. Rosenfeld, G.M. Argast, P.C. Heinrich, and N. Fausto. 2001. Expression of suppressors of cytokine signaling during liver regeneration. Journal of Clinical Investigation 107: 1285–1292. CrossRef
- Senn, J.J., P.J. Klover, I.A. Nowak, and R.A. Mooney. 2002. Interleukin-6 induces cellular insulin resistance in hepatocytes. Diabetes 12: 3391–3399. CrossRef
- Liu, Y.F., A. Herschkovitz, H.S. Boura, D. Ronen, K. Paz, D. Leroith, and Y. Zick. 2004. Serine phosphorylation proximal to its phosphotyrosine binding domain inhibits insulin receptor substrate 1 function and promotes insulin resistance. Molecular and Cellular Biology 24: 9668–9681. CrossRef
- Liu, Y.F., K. Paz, A. Herschkovitz, A. Alt, T. Tennenbaum, S.R. Sampson, M. Ohba, T. Kuroki, D. LeRoith, and Y. Zick. 2001. Insulin stimulates PKCzeta-mediated phosphorylation of insulin receptor substrate-1 (IRS-1). A self-attenuated mechanism to negatively regulate the function of IRS proteins. Journal of Biological Chemistry 276: 14459–14465.
- Park, E., V. Wong, X. Guan, A.I. Oprescu, and A. Giacca. 2007. Salicylate prevents hepatic insulin resistance caused by short-term elevation of free fatty acids in vivo. Journal of Endocrinology 2: 323–331. CrossRef
- Shi, Shu, Liu Xiaomei, Song Lina, Zhou Jinfang, Song Jumin. 2009. Effect of berberine on the gene expression of IRS-1/-2, p85 in 2-type diabetic rats. Zhejiang Journal of Traditional Chinese Medicine 44: 254–257.
- Toker, A., and A.C. Newton. 2000. Akt/protein kinase B is regulated by autophosphorylation at the hypothetical PDK-2 site. Journal of Biological Chemistry 12: 8271–8274. CrossRef
- Kim, S.H., E.J. Shin, E.D. Kim, T. Bayaraa, S.C. Frost, and C.K. Hyun. 2007. Berberine activates GLUT1-mediated glucose uptake in 3 T3-L1 adipocytes. Biological & Pharmaceutical Bulletin 30: 2120–2105. CrossRef
- Berberine Inhibits Inflammatory Response and Ameliorates Insulin Resistance in Hepatocytes
Volume 34, Issue 6 , pp 659-667
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- insulin resistance
- Industry Sectors
- Author Affiliations
- 1. Department of Gerontology, Hospital of Traditional Chinese Medicine of Nanjing, 1 Jinglin Road, Nanjing, 210001, People’s Republic of China
- 2. Department of Pharmacology of Chinese Materia Medica, China Pharmaceutical University, 24 Tong Jia Xiang, Nanjing, 210009, People’s Republic of China